Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2006-08-08
2006-08-08
Haddad, Maher (Department: 1644)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S391300
Reexamination Certificate
active
07087724
ABSTRACT:
The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.
REFERENCES:
patent: 4758524 (1988-07-01), Bundesen et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5091513 (1992-02-01), Huston et al.
patent: 5837821 (1998-11-01), Wu
patent: 6056957 (2000-05-01), Chou et al.
patent: 6132719 (2000-10-01), Kohno et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6180377 (2001-01-01), Morgan et al.
patent: 6632927 (2003-10-01), Adair et al.
patent: 0 239 400 (1987-09-01), None
patent: 0 347 933 (1989-12-01), None
patent: WO 91/02547 (1991-03-01), None
patent: WO 94/09034 (1994-04-01), None
patent: WO 98/52976 (1998-11-01), None
Lewis Securities Ltd. http://www.comupdate.com.au/issues/dec98.htm, pp. 1-4, Dec. 1998.
Bautovich G, et al. Detection of deep venous thrombi and pulmonary embolus with technetium-99m-DD-3B6/22 anti-fibrin monoclonal antibody Fab' fragment. J Nucl Med. Feb. 1994;35(2):195-202.
Biovation Therapeutic Antibodies J591 and 3B6 Antibodies. http://www.biovation.co.uk/pages/products/1/. pp. 1, 2004.
Rudikoff et al. Single amino acid substitution altering antigen-binding specificity. Proc Natl Acad Sci U S A. Mar. 1982;79(6):1979-83.
Panka et al. Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies. Proc Natl Acad Sci U S A. May 1988;85(9):3080-4.
Attwood TK. Genomics. The Babel of bioformatics. Science. Oct. 2000:290(5491):471-3.
Skolnick et al. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Biotechnol. Jan. 2000;18(1):34-9.
Adams, G.P. et al. (Sep. 1, 1993). “Highly Specificin Vivotumor Targeting by Monovalent and Divalent Forms of 741F8 Anti-c-erbB-2 Single-Chain Fv,”Cancer Research53:4026-4034.
AGEN Media Release. (Feb. 1, 2001) “Major Development in Agen/BII Blood Clot Imaging Technology,” AGEN Biomedical Limited—Media Release located at <http://web.archive.org/web/2001602122513/www.agen.com.au
ews/mr011.htm> visited on Sep. 7, 2002 (2 pages).
Altschul, S.F. et al. (1997). “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,”Nucl. Acids Res. 25(17):3389-3402.
Ausubel, F.M. et al. eds. (2001). “Chapter 15: Polymerase Chain Reaction” InCurrent Protocols in Molecular BiologyJohn Wiley & Sons Inc., vol. 3, Supplementa 56, pp. 1-2, 15.0.1-15.6.9.
Bautovich, G. et al. (Feb. 1994). “Detection of Deep Venous Thrombi and Pulmonary Embolus with Technetium-99m-DD-3B6/22 Anti-fibrin Monoclonal Antibody Fab' Fragment,”Journal of Nuclear Medicine35(2):195-202.
Bechtol, K.B. (1981). “Quantitative Absorption/Blocking Assay,”In Monoclonal Antibodies Hybridomas:A New Dimension in Biological AnalysesPlenum Press, New York, New York, pp. 383-384.
Bechtol, K.B. (1981). “Radioimmunoassay,”In Monoclonal Antibodies Hybridomas:A New Dimension in Biological AnalysesPlenum Press, New York, New York, pp. 381-382.
Bonner, T.I. et al. (1973). “Reduction in the Rate of DNA Reassociation by Sequence Divergence,”J. Mol. Biol. 81(2):123-135.
Budzynski. A. Z. et al. (1979). “Antigenic Markers on Fragment DD, A Unique Plasmic Derivative of Human Crosslinked Fibrin,”Blood54(4):794-804.
Chothia, C. and Lesk, A.M. (1987). “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J. Mol. Biol, 196:901-917.
Chothia, C. et al. (1992). “Structural Repertoire of the Human VHSegments,”J. Mol. Biol. 227:799-817.
Coligan et al., eds. (1991-1997). inCurrent Protocols in Immunology, vol. 1, John Wiley & Sons, Inc., USA, Supplement 54, Table of Contents pp. 1-10.
Cumber, A.J. et al. (1992). “Comparative Stabilities in Vitro and in Vivo of a Recombinant Mouse Antibody FvCys Fragment and bisFvCys Conjugate,”J. Immunol. 149(1):120-126.
Dauherty, B.L. et al. (1991). “Polymerase chain reaction facilitates the cloning, CDR-grating, and rapid expression of a murine nonoclonal antibody directed against the CD18 component of leukocyte integrins,”Nucleic Acids Research19(9):2471-2476.
Davies, J. and Riechmann, L. (1994). “‘Camelising’ human antibody fragments:NMR studies on VH domains,”FEBS Lett. 339:285-290.
Foung, S.K.H. et al. (1986). “Generation of Human Monoclonal Antibodies by Fusion of EBV-Activated B Cells to a Human-Mouse Hybridoma,” Chapter 13In Methods in Enzymology—vol. 121, Immunochemical Techniques, Part I, Hybridoma Technology and Monoclonal Antibodies, Langone and Vunakis Editors, Academic Press, Inc. New York, pp. 168-174.
Gefter, M.L. et al. (1977). “A Simple Method for Polyethylene Glycol-Promoted Hybridization of Mouse Myeloma Cells,”Somatic Cell Genet. 3(2):231-236.
Glockshuber, R. et al. (1990). “A Comparison of Strategies To Stabilize Immunoglobulin Fv- Fragments”Biochem. 29:1362-1367.
Graeff , H and Halfer, R. (1982). “Detection and Relevance of Cross-linked Fibrin Derivatives in Blood,”Seminars in Thrombosis and Hemostatis8(1):57-68.
Hamers-Casterman, C. et al. (1993). “Naturally occurring antibodies devoid of light chains,”Nature363:446-448.
Jonak, Z.L. (1981). “Peroxidase-Conjugated Antiglobulin Method for Visual Detection of Cell-Surface Antigens,”In Monoclonal Antibodies Hybridomas:A Dimension in Biological AnalysesPlenum Press, New York, New York, pp. 378-380.
Jones, P.T. et al. (1986). “Replacing the complementarity-determining regions in a human antibody with those from a mouse,”Nature321:522-525.
Kabat, E.A. et al. (1991).Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, 5th edition, NIH Publication No. 91-3242, pp. iii-xi. (Table of Contents).
Kennett, R.H. (1981). “Enzyme-Linked antibody Assay with Cells Attached to Polyvinyl Chloride Plates,”In Monoclonal Antibodies Hybridomas:A Dimension in Biological AnalysesPlenum Press, New York, pp. 376-377.
Kohler, G. and Milstein, C. (1975). “Continuous cultures of fused cells secreting antibody of predefined specificity,”Nature256:495-497.
Kohler, G. and Milstein, C. (1976). “Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion,”Eur. J. Immunol. 6(7):511-519.
Kostelny, S.A. et al. (1992). “Formation of a Bispecific Antibody by the Use of Leucine Zippers,”J. Immunol. 148(5):1547-1553.
Krebber, A. et al. (1997). “Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system,”J. Immunol. Methods201(1):35-55.
Ku, J. and Schutz, P.G. (1995). “Alternate protein frameworks for molecular recogniton,”Proc. Natl. Acad. Sci. USA92:6552-6556.
Liu, A.Y. et al. (1987). “Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells,”Proc. Natl. Acad. Sci. USA84:3439-3443.
Marmur, J. and Doty, P. (1962). “Determination of the Base Composition of Deoxzyribonucleic Acid from its Thermal Denaturation Temperature,”J. Mol. Biol. 5:109-118.
Orlandi, R. et al. (1989). “Cloning immunoglobulin variable domains for expression by the polymerase chain reaction,”Proc. Natl. Acad. Sci. USA86:3833-3837.
Pack, P. and Plünckthun, A. (1992). “Miniantibodies:Use of Amphipathic Helices To Produce Functional, Flexibly Linked Dimeric FvFragments with High Avidity inEscherichia coli,”Biochem. 31(6):1579-1584.
Plückthun, A. et al. (1996). “Producing Antibo
Carr Francis J.
Hamilton Anita A.
Agen Biomedical Ltd
Haddad Maher
Robins & Pasternak LLP
LandOfFree
Carrier molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carrier molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carrier molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3632741